Parnassus Investments LLC Has $47.44 Million Stake in Insulet Corporation $PODD

Parnassus Investments LLC boosted its stake in Insulet Corporation (NASDAQ:PODD) by 10.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 166,904 shares of the medical instruments supplier’s stock after buying an additional 16,205 shares during the period. Parnassus Investments LLC’s holdings in Insulet were worth $47,441,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PODD. NewEdge Advisors LLC boosted its stake in Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares in the last quarter. Cresset Asset Management LLC boosted its stake in Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after buying an additional 177 shares in the last quarter. Cerity Partners LLC boosted its stake in Insulet by 68.7% in the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after buying an additional 7,030 shares in the last quarter. Sei Investments Co. boosted its stake in Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after buying an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its stake in Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after buying an additional 791 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. TD Cowen decreased their price target on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a research note on Monday, June 1st. Bank of America reduced their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Leerink Partners reduced their price objective on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Finally, Sanford C. Bernstein reduced their price objective on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus target price of $240.78.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by insiders.

Insulet Trading Down 1.0%

PODD stock opened at $149.19 on Friday. The company has a market cap of $10.33 billion, a P/E ratio of 34.70, a PEG ratio of 1.19 and a beta of 1.13. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The business has a fifty day moving average of $171.07 and a 200-day moving average of $233.25.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts expect that Insulet Corporation will post 6.46 EPS for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.